Metformin use in prediabetes
Pro Research Analysisby 
Searched over 200M research papers
Prevalence and Patterns of Metformin Use in Prediabetes
Despite strong evidence supporting metformin for diabetes prevention, its use among people with prediabetes remains very low in both the U.S. and internationally. Studies show that less than 1% of U.S. adults with prediabetes use metformin, even among those with additional risk factors such as high BMI, younger age, or a history of gestational diabetes, for whom guidelines recommend its use 138. Similar low rates are observed in other countries, such as Saudi Arabia, where only about 7% of prediabetic patients received metformin, with slightly higher use among those most likely to benefit .
Effectiveness of Metformin in Preventing Type 2 Diabetes
Metformin has been shown to significantly reduce the risk of developing type 2 diabetes in people with prediabetes, especially those at higher risk. The greatest benefit is seen in individuals with higher fasting plasma glucose (FPG) at baseline or more pronounced impaired fasting glucose (IFG), where metformin reduced diabetes incidence by up to 43% 2467+1 MORE. Metformin also helps stabilize insulin sensitivity and is more effective in those with higher baseline insulin sensitivity .
Guidelines and Recommendations for Metformin Use
Major guidelines, including those from the American Diabetes Association (ADA), recommend considering metformin for prediabetes patients who are younger than 60, have a BMI of 35 kg/m² or higher, have a history of gestational diabetes, or have rising HbA1c or fasting glucose levels 1346+2 MORE. Despite these recommendations, real-world adoption is limited, possibly due to provider hesitancy, lack of awareness, or reluctance to medicalize prediabetes 138.
Metformin’s Safety, Cost-Effectiveness, and Additional Benefits
Metformin is widely regarded as safe, well-tolerated, and cost-effective for diabetes prevention, with decades of clinical use supporting its profile 468. Economic analyses confirm its cost-effectiveness, particularly in high-risk groups . Additionally, metformin may offer cardiovascular benefits, especially in morbidly obese patients with prediabetes, where its use is associated with lower incidence of cardiovascular disease .
Special Considerations: Metformin Use in Women and Perimenopausal Populations
Metformin’s effectiveness and side effect profile may differ by sex and menopausal status. Evidence suggests it may be particularly beneficial for perimenopausal women, potentially due to its effects on weight, inflammation, and hormonal regulation. It also shows promise in managing related conditions such as polycystic ovary syndrome (PCOS) and endometrial disorders . However, more research is needed to tailor guidelines for this population .
Barriers to Metformin Use and the Role of Healthcare Providers
Key factors influencing metformin use include younger age, female sex, higher BMI, and direct physician recommendation. Awareness of prediabetes and a history of gestational diabetes also increase the likelihood of metformin use. However, perceived threat or benefits and self-efficacy are less influential than provider cues to action, highlighting the importance of proactive, patient-centered care and shared decision-making .
Conclusion
Metformin is an effective, safe, and cost-efficient option for preventing type 2 diabetes in high-risk prediabetic individuals, especially those with higher BMI, younger age, or a history of gestational diabetes. Despite strong evidence and clear guidelines, its real-world use remains low. Increasing provider awareness and proactive patient engagement are essential to improve uptake and reduce the burden of diabetes.
Sources and full results
Most relevant research papers on this topic